Peter’s practice involves intellectual property enforcement and defense, and client counseling on issues related to IP rights. Peter's primary focus is in patent litigation where he has experience in every phase from pre-suit investigations through appeal, including, initial evaluation and case initiation, fact and expert discovery, pre-and post-trial motion practice, and trials and appeals. In addition to suits centered on the assertion and defense of infringement claims, Peter has experience with the successful resolution of multiple inventorship disputes and related misappropriation claims.
Peter has represented clients across a wide range of technologies such as biotechnology inventions, automotive parts, medical and mechanical devices, consumer products. He has also worked on numerous high-stakes Hatch-Waxman litigations for major pharmaceutical companies through trial and appeals. In addition to patent litigation, Peter has experience in disputes involving breach of contracts, unfair competition, trademarks and trade secret misappropriation claims.
Peter is a registered patent attorney licensed to practice and argue before the United States Patent and Trademark Office. In addition to representing clients in US District Courts and the US Court of Appeals for the Federal Circuit, he has experience in multiple post-grant proceedings before the Patent Trial and Appeal Board and its predecessor. He also provides patent and product analyses, and evaluations of prior art related to infringement and invalidity opinions.
Prior to joining the firm, he practiced in the intellectual property litigation practice in the Boston office of another international law firm. Peter also previously worked in and supervised an academic laboratory focused on researching infectious diseases. He is a co-author on multiple scientific papers and spent time in Zambia investigating the co-infection of measles and HIV. During law school, Peter was an editor on the Boston University Journal of Science and Technology Law and worked as a research assistant in intellectual property and the Health Law Department.
More Legal and Business Bylines From Peter J. Cuomo
- Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out - (Posted On Thursday, April 25, 2024)
- How Your Trade Secret Could Help to Defend Against Claims of Patent Infringement - (Posted On Thursday, February 01, 2024)
- Inherent Limitations in Prior Patents can Lead to Obviousness-Type Double-Patenting - (Posted On Thursday, December 21, 2023)
- Federal Circuit Puts the Onus on Patent Owners to Disclaim Patent Term or Face Double-Patenting - (Posted On Thursday, September 07, 2023)
- Federal Circuit Clarifies That Secondary Considerations Must Be Considered Both Individually and as a Whole in an Obviousness Analysis - (Posted On Thursday, August 31, 2023)
- Supreme Court Unanimously Affirms Amgen Repatha® Antibody Patents Invalid for Lack of Enablement - (Posted On Thursday, May 25, 2023)
- Making Bacon Still Requires a Significant Contribution for Joint Inventorship - (Posted On Friday, May 12, 2023)
- Federal Circuit Affirms Delisting of REMS System Patent from FDA Orange Book - (Posted On Monday, March 06, 2023)
- Federal Circuit Resolves District Court Split, Holds Foreign Defendant Cannot Defeat Rule 4(k)(2) Personal Jurisdiction by Unilateral Post-suit Consent to Jurisdiction in Alternative Forum - (Posted On Monday, January 23, 2023)
- Southern District Magistrate Judge Holds That Pleading Willful Patent Infringement Does Not Require Allegations of “Egregious” Infringing Activity and That Requisite Knowledge May Be Provided by a Prior Complaint in the Same Action - (Posted On Tuesday, January 03, 2023)